NCT05651178 2025-01-07
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Recruiting
Clinical Trials
5 trialsNCT06732232 2024-12-13
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1 Recruiting
NCT04626752 2020-11-13
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03661554 2018-09-10
BCMA CAR-T
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Phase EARLY_PHASE1 Unknown
NCT03559764 2018-06-18
Study of BCMA CAR-T in Multiple Myeloma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown